BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22945560)

  • 1. Ovarian cancer: biomarker proteomic diagnosis in progress.
    Zhang Y; Guo B; Bi R
    Appl Biochem Biotechnol; 2012 Oct; 168(4):910-6. PubMed ID: 22945560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Identification of new ovarian cancer biomarkers with proteomic analyses--the diagnostic tool of the future?].
    Petri AL; Høgdall E; Engelholm SA; Christensen IJ; Kjaer SK; Høgdall CK
    Ugeskr Laeger; 2007 Aug; 169(33):2614-9. PubMed ID: 17725906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomics and biomarkers for ovarian cancer diagnosis.
    Zhang B; Barekati Z; Kohler C; Radpour R; Asadollahi R; Holzgreve W; Zhong XY
    Ann Clin Lab Sci; 2010; 40(3):218-25. PubMed ID: 20689132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions.
    Jurisicova A; Jurisica I; Kislinger T
    Expert Rev Proteomics; 2008 Aug; 5(4):551-60. PubMed ID: 18761466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current clinical use of biomarkers for epithelial ovarian cancer.
    Moore RG; Maclaughlan S
    Curr Opin Oncol; 2010 Sep; 22(5):492-7. PubMed ID: 20613519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of proteomics in ovarian cancer: which sample should be used?
    Cadron I; Van Gorp T; Timmerman D; Amant F; Waelkens E; Vergote I
    Gynecol Oncol; 2009 Dec; 115(3):497-503. PubMed ID: 19811810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Searching for a system: the quest for ovarian cancer biomarkers.
    Rodland KD; Maihle NJ
    Cancer Biomark; 2010-2011; 8(4-5):223-30. PubMed ID: 22045355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Status of tumor markers in epithelial ovarian cancer has there been any progress? A review.
    Husseinzadeh N
    Gynecol Oncol; 2011 Jan; 120(1):152-7. PubMed ID: 20934205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer screening: a look at the evidence.
    Fields MM; Chevlen E
    Clin J Oncol Nurs; 2006 Feb; 10(1):77-81. PubMed ID: 16482731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HE4 in ovarian cancer: from discovery to clinical application.
    Montagnana M; Danese E; Giudici S; Franchi M; Guidi GC; Plebani M; Lippi G
    Adv Clin Chem; 2011; 55():1-20. PubMed ID: 22126021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular diagnostics of ovarian cancer using proteome techniques].
    Vlasova MA; Moshkovskiĭ SA; Safarova MP; Makarov OV; Archakov AI
    Biomed Khim; 2005; 51(4):367-83. PubMed ID: 16223028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone.
    White NM; Mathews M; Yousef GM; Prizada A; Fontaine D; Ghatage P; Popadiuk C; Dawson L; Doré JJ
    Cancer Biomark; 2009; 5(6):279-87. PubMed ID: 20037204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and application of protein biomarkers for ovarian cancer.
    Gagnon A; Ye B
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):9-13. PubMed ID: 18196999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of biomarkers for the ovarian cancer diagnosis.
    Zhang B; Cai FF; Zhong XY
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):119-23. PubMed ID: 21632171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer.
    Kim YW; Bae SM; Kim IW; Liu HB; Bang HJ; Chaturvedi PK; Battogtokh G; Lim H; Ahn WS
    Oncol Rep; 2012 Aug; 28(2):585-91. PubMed ID: 22641176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic studies of early-stage and advanced ovarian cancer patients.
    Wang J; Zhang X; Ge X; Guo H; Xiong G; Zhu Y
    Gynecol Oncol; 2008 Oct; 111(1):111-9. PubMed ID: 18703221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
    Jones MB; Krutzsch H; Shu H; Zhao Y; Liotta LA; Kohn EC; Petricoin EF
    Proteomics; 2002 Jan; 2(1):76-84. PubMed ID: 11788994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer.
    Høgdall C; Fung ET; Christensen IJ; Nedergaard L; Engelholm SA; Petri AL; Risum S; Lundvall L; Yip C; Pedersen AT; Hartwell D; Lomas L; Høgdall EV
    Gynecol Oncol; 2011 Nov; 123(2):308-13. PubMed ID: 21855971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteins' promise--progress and challenges in ovarian cancer proteomics.
    Koehn H; Oehler MK
    Menopause Int; 2007 Dec; 13(4):148-53. PubMed ID: 18088525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma.
    Chung KH; Lee DH; Kim Y; Kim TH; Huh JH; Chung SG; Lee S; Lee C; Ko JJ; An HJ
    J Proteome Res; 2010 Jan; 9(1):451-7. PubMed ID: 19902980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.